Moreover, the 36-month beta value for TNDM is 1.30. Analysts have varying opinions on the stock, with 11 analysts rating it as a “buy,” 4 as “overweight,” 6 as “hold,” and 0 as “sell.”
The public float for TNDM is 65.18M and currently, short sellers hold a 9.26% of that float. On January 03, 2025, TNDM’s average trading volume was 1.38M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
TNDM) stock’s latest price update
Tandem Diabetes Care Inc (NASDAQ: TNDM)’s stock price has gone decline by -0.50 in comparison to its previous close of 36.02, however, the company has experienced a -3.14% decrease in its stock price over the last five trading days. zacks.com reported 2024-12-13 that Tandem Diabetes’ t:slim X2 insulin pump is now compatible with Dexcom G7 CGM in Canada.
TNDM’s Market Performance
TNDM’s stock has fallen by -3.14% in the past week, with a monthly rise of 10.24% and a quarterly drop of -12.95%. The volatility ratio for the week is 4.26% while the volatility levels for the last 30 days are 5.11% for Tandem Diabetes Care Inc The simple moving average for the last 20 days is 4.39% for TNDM’s stock, with a simple moving average of -8.13% for the last 200 days.
Analysts’ Opinion of TNDM
Many brokerage firms have already submitted their reports for TNDM stocks, with Morgan Stanley repeating the rating for TNDM by listing it as a “Overweight.” The predicted price for TNDM in the upcoming period, according to Morgan Stanley is $45 based on the research report published on December 02, 2024 of the previous year 2024.
Bernstein, on the other hand, stated in their research note that they expect to see TNDM reach a price target of $42. The rating they have provided for TNDM stocks is “Outperform” according to the report published on November 06th, 2024.
Goldman gave a rating of “Neutral” to TNDM, setting the target price at $46 in the report published on October 04th of the previous year.
TNDM Trading at 10.25% from the 50-Day Moving Average
After a stumble in the market that brought TNDM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -33.25% of loss for the given period.
Volatility was left at 5.11%, however, over the last 30 days, the volatility rate increased by 4.26%, as shares surge +7.40% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +5.07% upper at present.
During the last 5 trading sessions, TNDM fell by -3.14%, which changed the moving average for the period of 200-days by +15.17% in comparison to the 20-day moving average, which settled at $34.33. In addition, Tandem Diabetes Care Inc saw -0.50% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TNDM starting from BLICKENSTAFF KIM D, who sale 30,000 shares at the price of $31.38 back on Nov 21 ’24. After this action, BLICKENSTAFF KIM D now owns 165,190 shares of Tandem Diabetes Care Inc, valued at $941,400 using the latest closing price.
BLICKENSTAFF KIM D, the Director of Tandem Diabetes Care Inc, sale 10,000 shares at $30.00 during a trade that took place back on Nov 20 ’24, which means that BLICKENSTAFF KIM D is holding 195,190 shares at $300,000 based on the most recent closing price.
Stock Fundamentals for TNDM
Current profitability levels for the company are sitting at:
- -0.14 for the present operating margin
- 0.44 for the gross margin
The net margin for Tandem Diabetes Care Inc stands at -0.13. The total capital return value is set at -0.19. Equity return is now at value -45.96, with -13.36 for asset returns.
Based on Tandem Diabetes Care Inc (TNDM), the company’s capital structure generated 0.59 points at debt to capital in total, while cash flow to debt ratio is standing at 0.02. The debt to equity ratio resting at 1.47. The interest coverage ratio of the stock is -22.27.
Currently, EBITDA for the company is -194.66 million with net debt to EBITDA at -4.29. When we switch over and look at the enterprise to sales, we see a ratio of 2.86. The receivables turnover for the company is 9.08for trailing twelve months and the total asset turnover is 1.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.90.
Conclusion
To wrap up, the performance of Tandem Diabetes Care Inc (TNDM) has been mixed in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
